CEO, GlaxoSmithKline Group
Andrew Witty became CEO of GSK on 21st May 2008.
Andrew joined Glaxo in 1985 and held a variety of roles in the UK business.
He has worked in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields and has been involved in multiple new product development programmes.
He then worked in South Africa and the USA prior to moving to Singapore where he led the Group’s operations as Senior Vice President, Asia Pacific. While in Singapore Andrew was a Board Member of the Singapore Economic Development Board, the Singapore Land Authority and in 2003 was awarded the Public Service Medal by the Government of Singapore.
In 2003 Andrew was appointed President of GSK Europe and joined GSK’s Corporate Executive Team.
Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China as well as the UK where he is currently a member of the Prime Minister’s Business Advisory Group and is the Lead Non-Executive Director for the Department of Business. He is also a member of the Board of INSEAD.
Andrew is President of the European Federation of Pharmaceutical Industry (EFPIA), a position he took up on 1 January 2010. Andrew has a Joint Honours BA in Economics from the University of Nottingham.
Please note that CVs have been provided by the speakers and the European Commission takes no responsibility for their contents.